TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01601509
Drug: Nasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
Study: NCT00454636
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
Study: NCT00454636
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 625 mg/m2, oral, twice daily per 3-week cycle
Study: NCT00454636
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2, oral, twice daily for 2 weeks
Study: NCT00197951
Drug: Treatment of psychiatric symptoms associated to alcoholism
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00963157
Drug: AS03
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
Study: NCT01328275
Drug: standard regimens according to the Thai Ministry of Public Health national guidelines
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
Study: NCT00996671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be used as comparator for GSK2256098
Study: NCT04514393
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous methotrexate at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 of all cycles，for up to 4 cycles.
Study: NCT00510510
Drug: NVA237 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhalation once a day for up to 28 days
Study: NCT00510510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to NVA237 dry powder inhalation once a day for up to 28 days
Study: NCT00510510
Drug: NVA237 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhalation once a day for up to 28 days
Study: NCT04426409
Drug: tarivid ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaseline ointment is applied to both noses.
Study: NCT01369277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of matching placebo in tablet formulation at the fasted state
Study: NCT03424291
Drug: Apatinib plus chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
Study: NCT02101567
Drug: Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
Study: NCT03529331
Drug: Hydrocodone/Acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
Study: NCT01482156
Drug: RAD001 + BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
Study: NCT03894800
Drug: Fentanyl (F1)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.025 mg i.v. and NaCl for inhalation will be administered(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Study: NCT03894800
Drug: Fentanyl (F2)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.05 mg i.v. and NaCl for inhalation will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Study: NCT00078793
Drug: Enbrel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept alone, etanercept plus methotrexate or other DMARDs
Study: NCT01125930
Drug: vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
Study: NCT02049203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00865605
Drug: Halobetasol Propionate 0.05% Ointment, single exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: A: Other Subjects received Alpharma/Purepac USHP formulated products
Study: NCT00865605
Drug: Ultravate® 0.05% ointment, single exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received Bristol-Myers Squibb Company formulated products
Study: NCT00409825
Drug: 17-OHPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
Study: NCT01724268
Drug: Pred + Meth
Approvals — FDA: no, EMA: no, PMDA: no
Description: PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
Study: NCT01724268
Drug: Anti TNF + Meth
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02995148
Drug: BAY987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-104)
Study: NCT02995148
Drug: SPF Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT02650752
Drug: Lapatinib in Tandem With Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02687256
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04132713
Drug: Capecitabine 150Mg Oral Tablet
Normalized name: Capecitabine 150mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced breast cancer patients with first-line medication
Study: NCT03942666
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet of CHF 6532
Study: NCT03942666
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet of CHF 6532
Study: NCT01478620
Drug: Canephron® N
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x 2 coated tablets/day for 7 days p.o.
Study: NCT01813656
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
Study: NCT00564525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication taken for 4 weeks
Study: NCT01045590
Drug: titration
Normalized name: Rebif Titration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
Study: NCT01045590
Drug: titration
Normalized name: Rebif Titration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the glibenclamide + rosiglitazone treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
Study: NCT00099736
Drug: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
Study: NCT00099736
Drug: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
Study: NCT00099736
Drug: MMF 2 g + full-dose Neoral (FDN) + corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
Study: NCT04130087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Placebo Tablet, identical appearance to experimental tablet.
Study: NCT00649870
Drug: Valtrex® Tablets 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg, single dose fed
Study: NCT00981240
Drug: SAR103168
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion
Study: NCT00895232
Drug: Cohort II
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00895232
Drug: Cohort III
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02841709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration matching the ACT-541468 capsules
Study: NCT04333706
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg BID
Study: NCT02333370
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
Study: NCT01929109
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01418157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT02690727
Drug: RP6530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT03105583
Drug: Medication use during pregnancy
Normalized name: PREGNANCY TEST
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03750565
Drug: TD-1473 - Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule/tablet, QD
Study: NCT03750565
Drug: TD-1473 - Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule/tablet, QD
Study: NCT03750565
Drug: TD-1473 - Dose C
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule/tablet, QD
Study: NCT03750565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule/tablet, QD
Study: NCT01645384
Drug: Atorvastatin Calcium Tablets, 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Study: NCT01578174
Drug: Normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
Study: NCT00783406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00941928
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
Study: NCT00089414
Drug: Ethinyl Estradiol/Drospirenone
Normalized name: ETHINYL ESTRADIOL/DROSPIRENONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug administered dependent upon arm.
Study: NCT00089414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05054868
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to the treatment group will receive oxycodone and ketorolac for postop pain management.
Study: NCT00089414
Drug: CDB 2914
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02221830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention utilizes a Placebo Camparator
Study: NCT00232973
Drug: ICXP007
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00998699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution subcutaneously administered every 4 weeks for 12 weeks
Study: NCT02336737
Drug: Technetium Tc99m Sulfur Colloid
Normalized name: Kit for the Prepartion of Technetium Tc99m Sulfur Colloid KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
Study: NCT02899130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive compound that is similar looking as the intervention
Study: NCT00356200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
Study: NCT02398188
Drug: LIPO-202
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02398188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02349061
Drug: Placebo Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenously at Week 0.
Study: NCT02349061
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously at Weeks 8 and 16.
Study: NCT00316719
Drug: LAM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
Study: NCT00316719
Drug: ADV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
Study: NCT01397162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching fluticasone propionate HFA MDI
Study: NCT00812253
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
Study: NCT03989700
Drug: Thiamine Mononitrate
Normalized name: Thiamine Mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
Study: NCT00541684
Drug: MK0954, /Duration of Treatment : 16 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03994107
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6.
Study: NCT04009616
Drug: Placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: rinsing with placebo mouthwash for 5 days.
Study: NCT04330872
Drug: Plain Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
Study: NCT03403049
Drug: Gemcitabine + Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy.
Study: NCT00255177
Drug: VGX-410 (Mifepristone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VGX-410 tablets taken daily or twice daily for 28 days
Study: NCT00255177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for VGX-410 tablets taken daily or twice daily for 28 days
Study: NCT03244774
Drug: POF
Normalized name: Ta-Poff
Approvals — FDA: no, EMA: no, PMDA: no
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study: NCT00055250
Drug: LY293111
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00055250
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02918162
Drug: Standard of care chemotherapy regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily.
Study: NCT01443065
Drug: 5-fluoro-uracil
Normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
Study: NCT01443065
Drug: AMG102
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg over 60 mn every 2 weeks up to progression or toxicity
Study: NCT02909140
Drug: Intracameral 0.2- 0.3ml of epinephrine 1:10,000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00361322
Drug: clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01384656
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
Study: NCT00131508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00128453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00028665
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide IV over 3-6 hours on day 16.
Study: NCT01462942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dose-matched placebo, twice per day
Study: NCT03978884
Drug: Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET
Normalized name: losartan/hydrochlorothiazide 50 mg-12.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 1 tab daily
Study: NCT03978884
Drug: Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET
Normalized name: losartan/hydrochlorothiazide 100 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 1 tab daily
Study: NCT01400113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Sublingual Tablet, single-dose
Study: NCT00453687
Drug: GSK233705
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational drug
Study: NCT01650324
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.